Search for: [Abstract = "re licensed for the use in Poland. Among theme, there were 84 medicinal products containing 25 active substances, and 5 emollients with official indication for the treatment of AE. Among the medicinal products both recommended by expert bodies and registered in Poland for the treatment of AE, clinical trials of high\- or moderate quality have confirmed the efficacy of active components of 36 medicinal products, including 2 topical calcineurin inhibitors \(pimecrolimus – 3 products, tacrolimus – 2 products\), oral ciclosporin \(12 medicinal products\), and 19 out of 45 topical preparations of glucocorticoids \(tGCS\) registered for the treatment of AE containing five active substances \(betamethasone dipropionate, mometasone furoate, hydrocortisone butyrate, fluticasone propionate, clobetasol propionate\). Thirty medicinal products \(containing 11 active substances\) registered for AE treatment were covered by the reimbursement scheme, among them 19 medicinal products contained any of 5 active substances, whose effectiveness in the treatment of AE was proven by high\- or moderate quality clinical trials \(mometasone furoate, hydrocortisone butyrate, fluticasone propionate, clobetasol propionate, ciclosporin\). Put together, there were 19 medicinal products available in Poland for the treatment of atopic eczema that were both recommended by expert bodies, officially licensed for the treatment"]
